Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 durcabtagene autoleucel study in relapsed and refractory multiple myeloma
2021-003747-22Phase 2Active
- Sponsor
- Novartis
- Start
- Dec 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durcabtagene autoleucel in multiple myeloma (MM), sponsored by Novartis. Primary endpoint: Best overall response per independent review committee. Started Dec 2021; status: active.
02
Drugs
durcabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2021-003747-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003747-22.